| Milestone | Year | Key Findings |
|-----------|------|--------------|
| Hit Identification | 2022 | High‑throughput screen of 1.2 M heterocyclic fragments → lead compound JQ‑001 (IC₅₀ = 1.2 µM). |
| Lead Optimization | 2023 | Structure‑guided modifications → JUQ‑063 (IC₅₀ = 12 nM). |
| In‑vitro Efficacy | 2023‑24 | - KRAS‑G12D‑mutant cell lines (MIA‑PaCa‑2, HCT116) → GI₅₀ = 25‑40 nM.
- Minimal activity in KRAS‑WT lines (IC₅₀ > 10 µM). |
| Pharmacokinetics (PK) | 2024 | Oral bioavailability ≈ 55 % (fasted rat), half‑life ≈ 12 h, low CYP3A4 induction. |
| In‑vivo Efficacy | 2024‑25 | - Orthotopic PDAC model (MIA‑PaCa‑2) → 78 % tumor growth inhibition (TGI) at 30 mg/kg QD.
- Combination with pembrolizumab → synergistic tumor regression (complete responses 18 %). |
| Safety/Toxicology | 2025 | GLP‑compliant 28‑day repeat‑dose study (rat & dog): No dose‑limiting toxicities up to 100 mg/kg; NOAEL established at 60 mg/kg. |
Key Take‑away: JUQ‑063 displays potent, selective inhibition of KRAS G12D with a favorable oral PK profile and an encouraging safety margin, making it a viable candidate for monotherapy or combination regimens. JUQ-063
If "JUQ-063" is a code for a specific type of paper, here are some general steps involved in producing paper: | Milestone | Year | Key Findings |
If you have more specific information about "JUQ-063," such as the intended use of the paper or the manufacturer, I could potentially provide more tailored information. If "JUQ-063" is a code for a specific
JUQ‑063 – An Overview
| Challenge | Impact | Mitigation Strategy | |-----------|--------|---------------------| | Resistance Mechanisms | Secondary KRAS mutations (e.g., Y96D) may restore signaling. | Combination trials with SHP2 inhibitors (e.g., RMC‑4630) to block upstream reactivation. | | Safety in Combination Regimens | Potential overlapping toxicities with immunotherapy or chemo. | Adaptive dose‑escalation designs; extensive PK/PD modeling; real‑time safety monitoring committees. | | Biomarker Access | Need for rapid KRAS G12D testing in community settings. | Deploy CDx kit with decentralized labs; partner with diagnostic networks (e.g., Guardant Health). | | Manufacturing Scale‑up | Complex heterocyclic synthesis may affect cost of goods. | Optimize synthetic route (continuous flow chemistry) and secure CMO partnerships early (e.g., WuXi). | | Regulatory Uncertainty | No precedent for KRAS G12D approvals. | Early engagement with FDA’s Oncology Center of Excellence (OCE); leverage accelerated pathways. |